Corporate Snapshot

TapImmune Inc. ("TapImmune" or "the Company") develops innovative immunotherapeutics to treat cancer and prevent infectious disease. Its product candidates are based on a core technology platform of transporters associated with antigen processing (TAP)—proteins that have a crucial role in the presentation of cancer markers on the surface of tumor cells. When TAP proteins are poorly expressed, tumors may go undetected by the immune system, progressing and possibly metastasizing (spreading) to other areas of the body. One of the Company's lead initiatives—a therapeutic cancer vaccine called AdhTAP1—aims to increase TAP expression in tumor cells in order to restore the immune system's ability to recognize and attack cancerous cells. Proof of principle for AdhTAP1 has been established through over 10 years of research at the University of British Columbia. TapImmune is preparing to initiate clinical manufacturing and toxicology studies for AdhTAP1 and submit an Investigational New Drug (IND) application in the U.S. and abroad in late 2011. As well, the Company is commencing the clinical development of a vaccine technology for breast cancer patients who express the HER-2/neu receptor, an indication of a more aggressive form of cancer. Phase I trials are expected in early 2011. TapImmune also aims to develop safe and effective preventive vaccines for infectious diseases (e.g., smallpox, influenza, and tuberculosis) based on findings that increasing TAP expression may augment the immune system's response to an infection. TapImmune plans to manage the development of its vaccine candidates through the Phase I/II proof-of-concept stage. In addition to its use as a stand-alone vaccine, TapImmune may be able to position the TAP technology as a "vaccine component" that improves the efficacy and potency of other vaccines.

*The Corporate Snapshot was last updated on June 21, 2010.

Latest Research

Executive
Informational
Overview

2010-06-21

Click to View

Stock Information (TPIV-OTC)